On June 30, 2026 Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, reported that the Research Council of Norway has approved a grant of NOK 16 million to Zelluna under the Innovation Project for the Industrial Sector (IPN) scheme.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NOK 16 million grant awarded by the Research Council of Norway
Funding will support Zelluna’s ongoing Phase 1 clinical study, ZIMA-101
The IPN scheme supports research-driven innovation projects in Norwegian industry and is administered by the Research Council of Norway
Award subject to final contract negotiations with the Research Council of Norway
"We are delighted to receive this support from the Research Council of Norway. The award provides meaningful funding for our Phase 1 clinical programme and represents strong external recognition of the innovation underpinning our TCR-NK platform and its potential to address significant unmet needs for patients with solid cancers," said Namir Hassan, CEO of Zelluna.
(Press release, Zelluna Immunotherapy, JUN 30, 2026, View Source [SID1234669029])